APLS Live signals | Maximize Profits with Getagraph.com

SELL 100 min ago

@ $48.63

Issued: 23 Apr 2024 @ 09:34

Return: 0.48%

Previous signal: Apr 22 - 15:56

Previous signal: Buy

Return: 2.16 %

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 11:14):

Stats
Today's Volume	397 226
Average Volume	1.34M
Market Cap	5.89B
EPS	$0 ( 2024-02-27 )
Next earnings date	( $-0.550 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.98
ATR14	$1.777 (3.64%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-18	Sullivan Timothy Eugene	Sell	14 164	Common Stock
2024-04-18	Sullivan Timothy Eugene	Buy	14 164	Common Stock
2024-04-12	Dunlop A. Sinclair	Buy	1 500	Common Stock
2024-04-12	Dunlop A. Sinclair	Sell	1 500	Stock Option (Right to Buy)
2024-04-08	Deschatelets Pascal	Buy	69 107	Common Stock

INSIDER POWER
2.42
Last 100 transactions
Buy: 1 047 810 \| Sell: 959 444

Volume Correlation

Long: -0.21 (neutral)

Short: -0.91 (very strong negative)

Signal:(35) Neutral

Apellis Pharmaceuticals Correlation

10 Most Positive Correlations
BRIVU	0.949
MSDAU	0.948
TIOAU	0.945
VLAT	0.945
NVCN	0.945
INZY	0.945
LDHA	0.943
GVCI	0.941
ALXN	0.941
TIOA	0.94

10 Most Negative Correlations
NDRA	-0.967
MNPR	-0.95
DFFN	-0.948
ENLV	-0.947
MMAT	-0.945
LSAQ	-0.945
JG	-0.942
ATNF	-0.942
MAGS	-0.941
ASRV	-0.938

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Apellis Pharmaceuticals Correlation - Currency/Commodity

0.49
( neutral )

0.80
( strong )

0.00
( neutral )

0.45
( neutral )

-0.38
( neutral )

0.13
( neutral )

Apellis Pharmaceuticals Financials

Annual	2023
Revenue:	$396.59M
Gross Profit:	$336.38M (84.82 %)
EPS:	$-4.45

Q4	2023
Revenue:	$146.38M
Gross Profit:	$126.47M (86.40 %)
EPS:	$-0.730

Q3	2023
Revenue:	$99.18M
Gross Profit:	$76.77M (77.41 %)
EPS:	$-1.170

Q2	2023
Revenue:	$94.97M
Gross Profit:	$86.59M (91.18 %)
EPS:	$-1.020

Financial Reports:

No articles found.

Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.